Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole plus palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study

被引：0
|
作者：
Hurvitz, Sara A.
Quiroga, Vanesa
Park, Yeon Hee
Bardia, Aditya
Lopez-Valverde, Vanesa
Steinseifer, Jutta
Fernando, Tharu M.
Spera, Gonzalo
Xue, Cloris
Fasching, Peter A.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-PD13-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD13-06
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
    Fasching, Peter A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso, Jose Luis
    Vasilyev, Alexander
    Adamchuk, Hryhoriy
    Salgado, Marcelo Ramos Tejo
    Yardley, Denise A.
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
    Hurvitz, Sara A.
    Bardia, Aditya
    Quiroga, Vanesa
    Park, Yeon Hee
    Blancas, Isabel
    Alonso-Romero, Jose Luis
    Vasiliev, Aleksandr
    Adamchuk, Hryhoriy
    Salgado, Marcelo
    Yardley, Denise A.
    Berzoy, Oleksandr
    Zamora-Aunon, Pilar
    Chan, David
    Spera, Gonzalo
    Xue, Cloris
    Ferreira, Erika
    Crnjevic, Tanja Badovinac
    Perez-Moreno, Pablo Diego
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Fernando, Tharu M.
    Moore, Heather M.
    LANCET ONCOLOGY, 2023, 24 (09): : 1029 - 1041
  • [3] Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study
    Hurvitz, S. A.
    Park, Y. H.
    Bardia, A.
    Quiroga, V.
    Lopez-Valverde, V.
    Steinseifer, J.
    Moore, H. M.
    Spera, G.
    Xue, C.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2021, 32 : S1285 - S1286
  • [4] Phase II neoadjuvant study of GDC-9545+palbociclib (palbo) vs anastrozole (A) plus palbo in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC)
    Hurvitz, Sara A.
    Fasching, Peter A.
    Park, Yeon Hee
    Quiroga, Vanesa
    Crnjevic, Tanja Badovinac
    Fresco, Rodrigo
    Lopez-Valverde, Vanesa
    Steinseifer, Jutta
    Ye, Chenglin
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Neoadjuvant giredestrant plus palbociclib (P) vs. anastrozole (A) plus P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2-eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study
    Park, Yeon Hee
    Quiroga, Vanesa
    Fasching, Peter A.
    Bardia, Aditya
    Lopez-Valverde, Vanesa
    Crnjevic, Tanja Badovinac
    Steinseifer, Jutta
    Devine, Jacob
    Hurvitz, Sara A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Exploratory gene expression analysis of coopERA Breast Cancer (BC): a study evaluating neoadjuvant giredestrant versus anastrozole alone and in combination with palbociclib in ER-positive, HER2-negative untreated early BC
    Chibly, Alejandro M.
    Fernando, Tharu M.
    Metcalfe, Ciara
    Hafner, Marc
    Owusu-Manu, Gilbert
    Hurvitz, Sara
    Bardia, Aditya
    Fasching, Peter A.
    Park, Yeon H.
    Quiroga, Vanesa
    Steinseifer, Jutta
    Perez-Moreno, Pablo
    Moore, Heather M.
    CANCER RESEARCH, 2023, 83 (05)
  • [7] Heart rate changes, cardiac safety, and exercise tolerance from a phase Ia/b study of giredestrant (GDC-9545) ± palbociclib in patients with estrogen receptor-positive, HER2-negative locally advanced/metastatic breast cancer
    Neilan, Tomas G.
    Villanueva-Vazquez, Rafael
    Bellet, Meritxell
    Lopez-Miranda, Elena
    Garcia-Estevez, Laura
    Kabos, Peter
    Bond, John
    Gates, Mary R.
    Chang, Ching-Wei
    Boni, Valentina
    CANCER RESEARCH, 2022, 82 (04)
  • [8] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [9] persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole plus palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2-LA/mBC).
    Turner, Nicholas C.
    Jhaveri, Komal L.
    Bardia, Aditya
    Niikura, Naoki
    Dieras, Veronique
    Barrios, Carlos H.
    Im, Seock-Ah
    Mueller, Volkmar
    Bellet, Meritxell
    Chang, Ching-Wei
    Ross, Graham A.
    Patre, Monika
    Loi, Sherene
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole plus palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2-LA/mBC)
    Mueller, Volkmar
    Turner, Nicholas
    Jhaveri, Komal
    Bardia, Aditya
    Niikura, Naoki
    Dieras, Veronique
    Barrios, Carlos
    Im, Seock-Ah
    Bellet, Meritxell
    Chang, Ching-Wei
    Ross, Graham
    Patre, Monika
    Loi, Sherene
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 25 - 25
12345